university website

A.M.M. Eggermont (Alexander) and D. Schadendorf (Dirk)

2009-06-01

Melanoma and Immunotherapy

Publication

Publication

Hematology / Oncology Clinics of North America , Volume 23 - Issue 3 p. 547- 564

About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

Additional Metadata
Keywords 4 1bb antibody, Antibodies, CD4 antibody, Cytokines, Immunotherapy, Melanoma, Review, Vaccines, adoptive immunotherapy, antibody, as 02b, as 15, bms 663513, cancer adjuvant therapy, cancer chemotherapy, cancer combination chemotherapy, cancer gene therapy, cancer immunization, cancer immunotherapy, cancer radiotherapy, cancer vaccine, canvaxin, carmustine, cd137 antibody, cisplatin, clinical trial, cnto 95, cytotoxic T lymphocyte antigen 4 antibody, dacarbazine, dendritic cell vaccine, drug bioavailability, drug megadose, fatigue, gene transfer, glycoprotein gp 100, histamine, human, immunological adjuvant, ipilimumab, low drug dose, melacine, melanoma, melanoma antigen 3, metastasis, neutropenia, nonhuman, peginterferon alpha, priority journal, recombinant alpha interferon, recombinant interleukin 15, recombinant interleukin 2, recombinant interleukin 21, recombinant protein, review, tamoxifen, temozolomide, tg 1024, ticilimumab, transaminitis, unclassified drug, unindexed drug, unspecified side effect, vinblastine, vitespen, volociximab
Persistent URL doi.org/10.1016/j.hoc.2009.03.009, hdl.handle.net/1765/16295
Journal Hematology / Oncology Clinics of North America
Organisation Erasmus MC: University Medical Center Rotterdam
Citation
Eggermont, A.M.M, & Schadendorf, D. (2009). Melanoma and Immunotherapy. Hematology / Oncology Clinics of North America (Vol. 23, pp. 547–564). doi:10.1016/j.hoc.2009.03.009
Full Text ( Final Version )


User Publication Person Organisation Collection
Close